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Food effectAbstract Ellagic acid (EA), a plant polyphenol known for its wide-range of health beneﬁts has lim-
ited use due to its low oral bioavailability. In this study, a new self-nanoemulsifying drug delivery
system (SNEDDS), based on the phospholipid complex technique, was developed to improve the
oral bioavailability of ellagic acid. Ellagic acid–phospholipid complex was prepared by an anti-sol-
vent method and characterized. Enhanced lipophilicity after the formation of ellagic acid–phospho-
lipid complex was veriﬁed through solubility studies.
Preliminary screening was carried out to select oil, surfactant and co-surfactant. Ternary phase
diagrams were constructed to identify the area of nanoemulsiﬁcation. Formulations were optimized
on the basis of globule size, cloud point and robustness to dilution. The optimized SNEDDS of ella-
gic acid–phospholipid complex showed mean globule size of 106 ± 0.198 nm and cloud point at 83–
85 C.
The in vitro drug release from SNEDDS was found to be higher compared to EA suspension and
complex, while ex vivo studies showed increased permeation from SNEDDS compared to EA sus-
pension. Moreover, SNEDDS overcome the food effect which was shown by EA suspension. Thus,
SNEDDS were found to be inﬂuential in improving the release performance of EA, indicating their
potential to improve the oral bioavailability of EA.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Over the past few decades, phytoconstituents, have infused a
great interest and have developed more prevalence in the phar-
maceutical industry and academia alike throughout the world
as safer and effective alternative to synthetic drugs. Despitethe
promising effectiveness and safety of phytoconstituents, poor
oral absorption due to their low aqueous solubility, rapid
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plasma drug concentration below MEC resulting in poor bio-
availability and less or no therapeutic effect which has ulti-
mately limited their clinical use.
Ellagic acid (EA), (2,3,7,8tetrahydroxy[1]benzopyrano
[5,4,3cde][1]benzopyran-5,10-dione), a dilactone of hexa-
hydroxydiphenic acid is a polyphenolic ﬂavonoid found in
many dietary plant foods such as walnuts, pomegranates,
strawberries, blackberries, cranberries, pecans and raspberries
(Ha¨kkinen et al., 2000). It has been reported that EA has many
beneﬁcial properties that help in the treatment of several oxida-
tion-linked chronic diseases (Landete, 2011; Li et al., 2013;
Vattem and Shetty, 2005) such as cardiovascular disease
(Larrosa et al., 2010), prostate cancer (Bell and Hawthorne,
2008), neurodegenerative diseases (Porat et al., 2006) and
breast cancer (Wang et al., 2012).
EA, an yellow ochre crystalline powder having melting
point of more than 300 C and a molecular weight of
302.02 Da, has poor solubility in water (9.7 lg/ml) and meth-
anol (671 lg/ml) but is soluble in N-methyl pyrrolidone
(NMP), pyridine, polyethylene glycol (400) and triethanola-
mine (Bala et al., 2006). Despite having several beneﬁcial
health effects, EA has limited potential for therapeutic use
due to poor absorption because of low aqueous solubility
(Lei et al., 2003), extensive metabolic transformation
(Seeram et al., 2004) and rapid elimination leading to ineffec-
tive drug plasma concentration.
Several techniques have been suggested to conquer this oral
bioavailability challenge of EA, including biodegradable in situ
gelling systems, liposomes, incorporation of EA in self-assem-
bled peptide microtubes and cellulose ester solid dispersions of
EA (Sharma et al., 2007; Carballo et al., 2010; Barnaby et al.,
2012; Li et al., 2013).
Recently, lipid based formulations have emerged as one of
the best and effective solution to deliver poorly soluble drugs,
among which, the self-nanoemulsifying drug delivery systems
(SNEDDS) have proved to be a promising technology to
enhance oral systemic bioavailability of poorly water soluble
drugs or phytoconstituents (Villar et al., 2012; Singh et al.,
2010; Hong et al., 2006).
SNEDDS are isotropic mixtures of active drug, oils, surfac-
tants and usually one or more hydrophilic co-solvents or co-
emulsiﬁers that on contact with aqueous medium upon mild
agitation, form ﬁne oil in water nanoemulsions of droplet sizes
ranging from 20 to 200 nm (Mou et al., 2008; Porter et al.,
2008). Thus small oil droplets of resulting nanoemulsions dis-
persed in the gastrointestinal ﬂuids provide a large interfacial
area for absorption enhancing the activity and minimizing
the irritation due to contact of drug in the gut wall
(Setthacheewakul et al. 2010).
It has also been observed that certain drug molecules are
not stable in lipid system which necessitates the presence of
antioxidants or chelating agents for enhancing their stability.
Thus SNEDDS containing antioxidants or chelating agents
provides formulation with improved bioavailability as well as
adequate stability.
Several studies have shown that complexing polyphenolic
compounds with phospholipids (PL) have improved their lipo-
solubility as well as aqueous solubility and thus its therapeutic
efﬁcacy (Pathan and Bhandari, 2011; Shyam et al., 2012; Singh
et al., 2012; Cao et al., 2012; Semalty et al., 2010; Khan et al.,
2013). Such technique has also facilitated the incorporation oflarge amount of low liposoluble compounds in lipid system
(Zhang et al., 2011). Apart from improving liposolubility of
polyphenolic compounds after complexation, PL themselves
have a hepatoprotective, antilipemic and anti-atherogenic
effects (Khan et al., 2013).
Thus, the purpose of this study was to develop and evaluate
a novel SNEDDS formulation of ellagic acid–phospholipid
complex (EAPL complex) stabilized by the presence of
antioxidant.2. Materials and methods
2.1. Materials
EA was purchased from Yucca Enterprises Pvt. Ltd, Mumbai,
India. Capmul MCM C8, and captex 500 were gifted by Abitec
Corp., USA. Capryol 90, labraﬁl M 2125 CS, labraﬁl M 2130
CS, labrafac CC, labrasol, lauroglycol FCC, transcutol P were
kindly gifted by Gattefosse, France. Oleic acid, tween 80,
tween 20, span 20, propylene glycol, PEG 400 and PEG 200
were purchased from Loba Chemie Pvt. Ltd., Mumbai. Crem-
ophor RH 40 was a gift from BASF, Germany.2.2. Preparation of EAPL complex by anti-solvent method
EAPL complex was prepared with EA and soy lecithin at a
molar mass ratio of 1:1 by a slightly modiﬁed method from
earlier reported method by Venkatesh et al. (2009). EA and
soy lecithin were placed in 100 mL round bottom ﬂask and
mixed properly. Then to this mixture 50 mL of methanol
was added. The mixture was reﬂuxed at a temperature not
exceeding 60 C for 2 h with continuous stirring. Resultant
solution was evaporated to 5–8 mL and 20 mL of n-hexane
was added to it with continuous stirring. EAPL complex was
precipitated, which was ﬁltered and dried under vacuum.
Resultant complex was collected and stored in a glass bottle
at room temperature (Kuntal et al., 2007).
2.3. Characterization of EAPL complex
2.3.1. Determination of EA content in EAPL complex
Content of EA in the complex was determined spectrophoto-
metrically. Approximately 10 mg of the complex was dissolved
in 1 mL of methanol in a 10 mL volumetric ﬂask and the vol-
ume was adjusted to 10 mL. A portion of the sample was ade-
quately diluted and analysed at 255 nm to evaluate the
concentration of EA in the complex. The experiments were
carried out in triplicate.
2.3.2. Thin layer chromatography (TLC)
EAPL complex, pure EA and physical mixture of EA and PL
were separately dissolved in ethyl acetate, spotted on Silica Gel
60 F254 pre-coated TLC plates and chromatogram was devel-
oped in a chromatographic chamber using chloroform: meth-
anol (70:30) as solvent system at room temperature. After
development of chromatogram, plates were exposed to iodine
fumes and scanned using ultra violet ﬂuorescence analysis
cabinet (Biomedica Oswal Scientiﬁcs, Pune, India) and the Rf
values of the spots were calculated and recorded.
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The infrared spectra of EAPL complex, pure EA, pure PL and
physical mixture of EA and PL were obtained by the KBr pel-
let method. Spectra were recorded in the region of 4000 cm1–
400 cm1.
2.3.4. Differential scanning calorimetry (DSC)
The peak transition onset temperature of EAPL complex, pure
EA and pure PL were determined and compared with the help
of a Mettler DSC 30 S (Mettler Toledo, UK). Samples were
sealed in the aluminium crimp cell and heated at the speed
of 10 C/min from 30 to 400 C in nitrogen atmosphere
(60 ml/min).
2.3.5. Determination of solubility
To conﬁrm the improved liposolubility of complex, solubility
of EAPL complex and EA were determined in n-octanol,
water, 0.1 N HCl, acetate buffer pH 4.5, phosphate buffer
pH 6.8. Excess amounts of EAPL complex and EA were added
to each microtube containing 1 mL of each solvent. Samples
were kept at 25 C with constant shaking on orbital shaker
for 48 h and then centrifuged (R-8C Laboratory Centrifuge,
Remi Equipments Pvt. Ltd., Mumbai.) at 6000 rpm for
10 min. Afterwards, supernatants were removed, ﬁltered to
remove undissolved particles and suitably diluted with respec-
tive solvents. The concentration of EA in supernatants was
quantiﬁed by UV spectroscopy at 255 nm. Each experiment
was carried out in triplicate.
2.4. Preparation of SNEDDS of EAPL complex
2.4.1. Screening of oil phase/surfactants/co-surfactants
Solubility of EAPL complex in different oils, surfactants and
co-surfactants were determined in similar manner as men-
tioned above. Screening of oil phase was made on the basis
of solubilization potential of oil phase for drug under investi-
gation. An excess amount of EAPL complex was added to
each microtube containing 1 mL of each vehicle. The concen-
tration of EAPL complex in supernatants was quantiﬁed by
UV spectroscopy at 255 nm as discussed in Section 2.3.4. Each
experiment was carried out in triplicate.
Surfactants were screened on the basis of their emulsifying
ability (Date and Nagarsenker, 2007). Each surfactant was
screened against selected oil phase for its ease of formation
of emulsion and percent transmittance. Brieﬂy, selected oil
phase and each surfactant in 1:1 ratio were mixed in capped
vials followed by dilution with equal volume of distilled water
to yield ﬁne emulsion. The ease of formation of emulsions was
observed by recording the number of volumetric ﬂask inver-
sions required to yield a uniform emulsion. The emulsions
were allowed to stand for 2 h and their percent transmittances
were recorded by UV spectroscopy at 638.2 nm using distilled
water as blank (Date et al., 2007).
Relative efﬁcacy of the co-surfactants to improve the nano-
emulsiﬁcation ability of the surfactants was assessed by the
turbidimetric method (Date et al., 2007). Brieﬂy, selected
surfactants and each co-surfactant in 1:1 ratio were mixed in
capped vials and this surfactant mixture were added to selected
oil phase in 2:1 ratio and their percent transmittances
were recorded by UV spectroscopy at 638.2 nm as described
above.2.4.2. Selection of antioxidant for stabilization of EA
Three different antioxidants (butyl hydroxyl toluene (BHT),
butyl hydroxyl anisole (BHA) and tocopherol) were screened
for their effectiveness in preventing EA from oxidation. Each
antioxidant was added to EA in the concentration of 0.15%
w/v and to it selected oil was added in capped vials while
one of the vials contained mixture of EA and oil without
any antioxidant. All the samples were heated at 70 C in
10 ml H2O2 for 3 h. Infrared spectra of all samples were
obtained by KBr pellet method to detect any interaction
between antioxidant and EA to select the best suited antioxi-
dant and also to conﬁrm stability of EA in the samples by
comparison with infrared spectra of pure EA.
2.4.3. Construction of the ternary phase diagram
Four SNEDDS systems were developed (Table 4). For each of
these systems (A, B, C, D), ternary phase diagrams were con-
structed to identify self-nanoemulsifying region, where each
apex of triangle represent 100% of oil, surfactant and co-sur-
factant respectively (Kommuru et al., 2001). By varying per-
centage of oil, surfactant and co-surfactant, twenty-seven
formulations were prepared for the phase diagram of each sys-
tem. Surfactant and co-surfactant were mixed in different vol-
ume ratios (1:1, 1:2 and 2:1). For each phase diagram, oil and
speciﬁc surfactant: co-surfactant ratio were mixed in ratios
ranging from 1:9 to 9:1 (w/w) in nine different ratios viz; 1:9,
2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1 (Villar et al., 2012). Only clear
or slight bluish dispersions were considered in the nanoemul-
sion region of the diagram (Zhang et al., 2008; Elnaggar
et al., 2009).
2.4.4. Preparation of EAPL complex SNEDDS
Fifteen formulations of the system D (Captex 500: Cremophor
RH 40: PEG 400), which yield maximum self-nanoemulsifying
area (Table 5), were selected for drug incorporation and fur-
ther optimization. EAPL complex at constant weight of
30 mg and antioxidant were dissolved in the surfactant/co-sur-
factant mixture (Smix) and gently shaken at 37 C for 5 min.
The oily phase was then added and shaking was proceeded
for 20 more min which was aided by sonication till a clear dis-
persion was obtained.
2.5. Optimization of SNEDDS formulations
Based on the former screening and ternary phase diagram
study, the optimum drug loaded formulation was selected
based on the following optimization criteria.2.5.1. Robustness to dilution
Robustness of the selected formulations for dilution was eval-
uated by diluting all these formulations to 50-, 100-, 250 and
1000-fold with distilled water. The diluted nanoemulsions
were allowed to stand for 2 h and monitored for any physical
changes and their percent transmittances were recorded by
UV spectroscopy at 638.2 nm using distilled water as blank.
2.5.2. Globule size analysis
In this analysis, the mean globule size and PDI of the selected
formulations after 1000-fold dilution in distilled water was
determined and compared. The globule size and PDI of the
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Zetasizer (Nano ZS 90, UK).2.5.3. Cloud point measurement
The cloud point value of ﬁfteen SNEDDS formulations was
determined and compared. Each formulation was diluted with
water in the ratio of 1:100 and placed in a water bath with
gradual increase (2/min) in temperature (from 25 to 80 C).
Cloud point was measured as the temperature at which there
was a sudden appearance of cloudiness as seen visually
(Zhang et al., 2008).Figure 1 TLC of (a) pure EA, (b) physical mixture of EA and PL
and (c) EAPL complex.2.6. Characterization of optimized EAPL complex SNEDDS
formulation
2.6.1. Zeta potential (ZP) measurement
Charge on drug loaded droplet surface was determined using
Zetasizer Beckman Coulter, Delsa TM Nano. Analysis time
was kept for 60 s and average ZP, charge and mobility of opti-
mized formulation of EAPL complex SNEDDS was deter-
mined. The zeta potential was measured after dilution of
samples with distilled water at room temperature.
2.6.2. Centrifugation test
The EAPL complex SNEDDS sample was diluted 100 times
with distilled water, centrifuged at 3500 rpm on centrifuge
for 30 min and then examined visually for any phase
separation.
2.7. Drug release studies
2.7.1. In vitro dissolution studies
In vitro dissolution tests were performed using a USP XXIV
dissolution apparatus 1 (Lab India DS 8000) at 37 ± 0.5 C
and rotating speed of 50 rpm in 900 mL of dissolution media
namely, 0.1 N HCl and phosphate buffer pH 6.8. SNEDDS
formulation equivalent to 15 mg of EA (30 mg of EAPL
complex) and EA suspension were ﬁlled in size ‘‘0’’ hard
gelatin capsules which were then placed in the rotating bas-
ket. At predetermined intervals, an aliquot (5 ml) of the sam-
ple was collected and ﬁltered through a membrane ﬁlter
(0.45 lm). The concentration of EA in the collected sample
was analysed using UV spectroscopic method at 255 nm.
An equivalent volume (5 ml) of fresh dissolution
medium was added to compensate for any loss due to
sampling.
2.7.2. In-vitro diffusion studies by dialysis bag method
Dialysis bag method were performed using USP XXIV disso-
lution apparatus 2 (Lab India DS 8000) at 37 ± 0.5 C and
rotating speed of 50 rpm in 900 mL of dissolution media
namely, 0.1 N HCl and phosphate buffer pH 6.8. SNEDDS
formulation and EA suspension in same amount as mentioned
above were ﬁlled in 6 · 3 cm dialysis bag (cut off 12,000 Da).
Both the ends of bag were tightly tied to prevent any leakage
and dialysis bag was ﬁxed to the rotating paddle. At predeter-
mined intervals, sampling and UV spectroscopic analysis of
samples were performed in similar manner as mentioned
above.2.8. Effect of food on release proﬁle of EA from unformulated
EA and EAPL complex loaded SNEDDS
2.8.1. Preparation of modiﬁed biorelevant media, blank fed state
simulated intestinal ﬂuid (FeSSIF) and blank fasted state
simulated intestinal ﬂuid (FaSSIF)
Blank FeSSIF was prepared by dissolving 3.438 g of NaH2PO4
and 6.186 g of NaCl in 500 ml of deionized water and pH was
adjusted to 6.5 by NaOH pellets. Similarly, Blank FaSSIF was
prepared by dissolving 8.65 g of acetic acid and 11.874 g of
NaCl in 500 ml of deionized water and pH was adjusted by
adding 4.04 NaOH pellets (Zoeller and Klein, 2007).
2.8.2. Dissolution studies
Release pattern of EA from unformulated EA and EAPL com-
plex loaded SNEDDS was studied using USPXXIII apparatus
I (Lab India DS 8000) at 37 ± 0.5 C with a rotating speed of
50 rpm in blank FeSSIF and FaSSIF separately so as to eval-
uate the effect of food on in vitro dissolution. During the study,
10 ml of the aliquot was removed at predetermined time inter-
vals (10, 15, 30, 45 and 60 min) from the dissolution medium
and replaced with fresh medium. The amount of EA released
in the dissolution medium was determined UV spectrophoto-
metrically at 255 nm.
2.9. Ex vivo permeability studies
For ex-vivo permeability study, stomach and small intestine of
the previously sacriﬁced Male Sprague–Dawley rat were iso-
lated and thoroughly washed with phosphate buffer saline
(PBS) to remove the mucous and lumen contents. EAPL com-
plex SNEDDS diluted separately with 0.1 N HCl and phos-
phate buffer pH 6.8 were ﬁlled in the stomach and intestine
respectively. An equivalent amount of EA suspension in
0.1 N HCl and phosphate buffer pH 6.8 respectively were used
for comparison. Both the ends of the tissues were tied properly
Figure 2 IR spectra of (a) EA, (b) PL, (c) physical mixture of EA and PL and (d) EAPL complex.
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40 ml of phosphate-buffered saline (pH 7.4) as the receptor
phase with continuous bubbling of air under gentle stirring
at 37 ± 2 C. Samples were withdrawn from the receptor
phase at periodic time intervals and subjected to spectrophoto-
metric analysis. All the experiments were performed in tripli-
cate (Gupta et al., 2011).
3. Results and discussion
3.1. Characterization of EAPL complex
3.1.1. Content of EA in complex
The content of EA in the complex, as determined by UV spec-
troscopy, was 95.89% (w/w). This may be attributed to strong
interaction between OH group of phenolic rings existing in the
structure of the EA molecule and aqueous head of phospho-
lipid molecule i.e. choline resulting in the formation of hydro-
gen bonding.
3.1.2. Thin layer chromatography (TLC)
The TLC chromatograms of pure EA and the EAPL complex
showed that pure EA has an Rf value of 0.309, whereas the
complex has Rf value of 0.476 (Fig. 1). Pure EA showed smal-
ler Rf value than that showed by complex which may be due to
the fact that the more polar component tends to adhere more
tightly to the plate whereas the less polar moiety tends to move
along more freely with the mobile phase consisting of chloro-Figure 3 DSC of (a) EA, (b)form and methanol. Results conﬁrmed the formation of EAPL
complex as complex showed different Rf value than that
showed by starting component i.e. pure EA.
3.1.3. Infra-red spectra analysis
The IR spectra of EA, PL, physical mixture of EA and PL,
EAPL complex are shown in Fig. 2. It is apparent that the
physical mixture and the complex have distinct IR spectra.
The characteristic absorption peak of EA at 1697.74 was
found in IR spectrum of EA and physical mixture but was
slightly shifted to 1621.93 in IR spectrum of complex. More-
over, broad peak in spectrum of EA at 3070.31 of OAH
appeared broader and with more intensity in the case of com-
plex indicating interactions between EA and PL. However, the
characteristic absorption peak of PL was found in spectrums
of both the complex and the physical mixture but appeared
narrower may be due to the formation of complex. Further-
more, no new peaks were observed in the mixture and
complex.
3.1.4. Differential scanning calorimetry (DSC) analysis
DSC is a fast and reliable method to screen drug-excipient
compatibility by providing maximum information about the
possible interactions between them. In DSC, an interaction
can be concluded by the elimination of endothermic peak(s),
appearance of new peak(s), changes in peak shape and its
onset, peak temperature/melting point and relative peak area
or enthalpy. Fig. 3 shows the DSC thermograms of (a) EA,PL and (c) EAPL complex.
Table 1 Solubility of ellagic acid and ellagic acid–phospho-
lipid complex in water and n-octanol at 25 C.
Solvent Solubility of ellagic
acid (mg/mL)
Solubility of ellagic
acid phospholipid complex
(mg/mL)
n-Octanol 0.138 ± 0.04 0.899 ± 0.02
Water 0.0108 ± 0.06 0.029 ± 0.03
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single peak (302.78 C) which is very sharp and it may be
caused by the phase transition from solid state to liquid state
or may have resulted from the decomposition of EA at such
higher temperature. PL showed two different kinds of endo-
thermal peaks. The ﬁrst endothermal peak (140.9 C) appears
mild, indicating movements due to heating of choline structure
of PL molecule. The second endothermal peak appears at
234.6 C, which could be possibly due to the phase transition
of PL molecule. DSC of EAPL complex showed that the endo-
thermal peaks of both, EA and PL disappeared and the phase
transition temperature appeared at 150.29 C, which may be
contributed to the formation of the complex and thus differed
from that of EA and PL. It was evident that the original peaks
of EA and PL disappeared from the thermogram of complex
and the phase transition temperature was lower than that of
EA. In this case, after combination of EA and polar parts of
PL molecule i.e. choline, the hydrocarbon chain in PL may
have twisted and enwrapped the choline bound portion of
PL molecule, causing the sequential energy to decrease in
phosphatidyl portion, which may have resulted in theFigure 4 Solubility of EA and EAPL
Figure 5 Solubility of EAPLdisappearance of the endothermal peak of PL and decline of
the melting point i.e. phase transition temperature.
3.1.5. Determination of solubility
Compared to EA, EAPL complex exhibited much higher solu-
bility in n-octanol and water, around 6 times and 3 times
respectively (Table 1). Results conﬁrmed that solubility of
EA was enhanced complexing it with PL which may be attrib-
uted to the amphipathic nature of phospholipids having con-
siderable solubility in both, aqueous and oily media. As pH
of the aqueous phase has considerable inﬂuence on the phase
behaviour of spontaneously emulsifying systems, therefore
enhancement of solubility of EA after complexation in all
pH ranges likely to be encountered was important. Solubility
of EA increased with an increase in pH. Moreover EAPL com-
plex also showed increase in its solubility with pH but was
higher at all pH conditions compared to EA as shown in Fig
4. So it conﬁrms the hypothesis that complexation is required
to increase its lipid and aqueous solubility before its incorpo-
ration into SNEDDS.
3.2. Screening of oil phase/surfactant/co-surfactant
Solubility studies were performed for the selection of oil phase
in order to determine individual solubilization capacity of each
oil phase for drug under investigation as solubilizing capacity
of an oily phase is an important consideration regarding oil
phase selection (Pouton and Porter, 2008). Also in self-nano-
emulsifying formulation to achieve optimum drug loading
identiﬁcation of the suitable oil, surfactant/co-surfactant hav-
ing maximal solubilizing potential for drug under investigationcomplex at different pH conditions.
complex in various oils.
Table 2 Emulsiﬁcation efﬁciency with different surfactants
and selected oils.
Surfactant % Transmittance at 638.2 nm
Lauroglycol 27.15
Labrafac WL 1349 48.44
Labraﬁl M 2125 0.49
Brij-35 93.45
Triton X-100 96.64
Tween 20 88.29
Tween 80 84.55
Cremophor RH 40 96.54
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drug was tested in four different oily phases (capmul CMC
C8, olive oil, captex 500, oleic acid, caproyl 90) that are fre-
quently used in developing self-emulsifying formulation
(Chen, 2008). Solubility of EAPL complex in various oily
phases, surfactants and co-surfactants solutions is presented
in Figs. 5–7, respectively. Solubility studies (Fig. 5) clearly
indicated that amongst the various oil phases that were
screened, captex 500 was found to solubilize maximum
amount of EAPL complex 1.680 ± 0.087 mg/mL followed by
caproyl 90 and olive oil 0.987 ± 0.139 mg/mL and 0.5
70 ± 0.012 mg/mL, respectively. The higher solubility of
EAPL complex in medium chain glycerides (captex 500,
capmul MCM C8 and caproyl 90) than long chain glycerides
may have arisen from the higher ester bond content per gram
of the medium chain glycerides. Therefore in order to achieve
ideal drug loading and to avoid precipitation of the drug on
dilution in the gut lumen in vivo, captex 500 was selected for
further study as it had maximum solubilizing capacity for
EAPL complex (Pouton, 2006).
Non-ionic surfactants are generally considered less toxic
and usually accepted for oral ingestion than ionic surfactants
(Pouton et al., 2008). A right combination of low and high
HLB surfactant is essential for the formation of a stable nano-
emulsion, in the development of a self-emulsifying formulation
(Craig et al., 1995; Pouton, 2000). In this study, eight different
hydrophilic and hydrophobic non-ionic surfactants were uti-
lized, amongst which few surfactants (tween 80, labrasol and
cremophor RH 40) are reported to possess bioactive effects.
These include inhibitory effects on p-gp and CYP enzymes
such as that of cremophor RH40 (Chen, 2008), effects on tight
junction such as by labrasol (Hu et al., 2001) and lymphotropic
character such as shown by tween 80 (Elnaggar et al., 2009).Figure 6 Solubility of EAPL co
Figure 7 Solubility of EAPL comThe surfactants were evaluated for their ability to emulsify
the selected oily phases. It has been reported that well formu-
lated SNEDDS is dispersed within seconds under gentle stir-
ring conditions (Pouton et al., 2008). Transmittance values
of different mixtures are demonstrated in Table 2. Emulsiﬁca-
tion studies clearly distinguished the ability of various surfac-
tants to emulsify captex 500. These studies indicated that
cremophor RH 40, triton X-100 and brij-35 had a very good
ability to emulsify captex 500 followed by tween 20 and tween
80, whereas, lauroglycol, labrafac WL 1349, labraﬁl M 2125
were found to be poor emulsiﬁers for captex 500. Good emul-
sifying ability of cremophor RH 40, triton X-100 and brij 35
may be contributed to their same length of carbon chain
(C8-C16) as that of selected oil phase. Even though, the
HLB values of the surfactants used in the study were in the
range of 1–16, there was a great dissimilarity in their emulsiﬁ-
cation ability. Obtained results are in line with those demon-
strated by Malcolmson et al. (1998) and Warisnoicharoen et al.
(2000) where they have concluded that microemulsiﬁcation alsomplex in various surfactants.
plex in various co-surfactants.
Table 3 Emulsiﬁcation efﬁciency with different co-surfactants
and selected surfactants.
Co-surfactant Cremophor RH 40
(% transmittance)
Triton X-100
(% transmittance)
Span 20 28.59 39.12
PEG 200 98.25 99.46
PEG 400 98.62 99.88
Propylene glycol 94.56 95.81
Table 4 Components of four SNEDDS systems.
System Oil phase Surfactant Co-surfactant
A Captex 500 Triton X-100 PEG 200
B Captex 500 Triton X-100 PEG 400
C Captex 500 Cremophor RH 40 PEG 200
D Captex 500 Cremophor RH 40 PEG 400
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shown in Fig. 6, solubilizing capacity for drug under investiga-
tion of cremophor RH40 and triton X-100 was higher than
that of the other surfactants and also both exhibited the
highest emulsiﬁcation efﬁciency with captex 500. Based on
solubilization potential, emulsiﬁcation ability and bioactive
features, cremophor RH40 and triton X-100 were selected
for further study.
Incorporation of a co-surfactant in the formulation con-
taining surfactant was reported to improve dispersibility and
drug absorption from the formulation (Porter et al., 2008).
In consideration of current investigation, four co-surfactants,
namely span 20, polyethylene glycol 400, polyethylene glycol
200 and propylene glycol were compared. The investigations
clearly demonstrated the ability of various co-surfactants to
improve the nanoemulsiﬁcation of selected surfactant/s. As
depicted in Table 3, captex 500 exhibited good emulsiﬁcation
with all co-surfactants, except span 20, with polyethylene gly-
col 400 showing maximum transmittance followed by polyeth-
ylene glycol 200. Moreover, results of solubility study
demonstrated in Fig. 7 concluded higher solubility in polyeth-
ylene glycol 400 and 200 as compared to other co-surfactants
which may be contributed to the fact that PEGs are miscible
with both aqueous as well as organic solvents. Moreover, phe-
nolic groups and lactone moiety in the structure of EA sug-
gests higher chances of solubility in solvents with which it
can form hydrogen bonds. Thus, hydrogen bonding might be
playing a major role in solubilization of EA in PEG 400.
Accordingly, PEG-400 and PEG-200, which gave higher trans-
mittance values and solubility, were selected as co-surfactants
for further investigations.
3.3. Screening of antioxidants
Due to the phenolic nature of EA which makes itself a power-
ful antioxidant, it gets oxidized in the presence of oil phase asFigure 8 Infrared spectra of (a) EA, (b) mixture (EA+captex 500),
mixture in the presence of butylated hydroxyl anisole, (e) mixture in tconﬁrmed by IR spectra of physical mixture of EA and captex
500. In SNEDDS formulation, oil phase is an essential compo-
nent which necessitates addition of another antioxidant in for-
mulation to prevent EA from being oxidized. Three oil soluble
antioxidants were screened for their potential to prevent oxida-
tion of EA in the presence of oil phase. From Fig. 8, it can be
clearly seen that in the presence of tocopherol, many character-
istic peaks of IR spectra of EA were retained even in the pres-
ence of oil phase (captex 500) while in case of BHT and BHA
these peaks disappeared indicating that these antioxidants
were not able to prevent oxidation of EA. Therefore it was
concluded that tocopherol (0.15% w/v) was able to prevent
oxidation of EA in the presence of oil phase and thus it was
selected as antioxidant in the development of SNEDDS formu-
lation (Solon et al., 2000; Festa et al., 2001).
3.4. Ternary phase diagram
Based on preliminary ‘screening studies, ternary phase dia-
grams of four different (oil: surfactant: co-surfactant) system
(Table 4) were constructed to identify self nanoemulsifying
area of each system. The phase diagrams are depicted in
Fig. 9. The shaded area in the triangle represents the region
of self-nanoemulsion region in which the SNEDDS form ﬁne
oil in water emulsion under gentle agitation. Surfactant and
co-surfactant are adsorbed at the interface, which reduces
the interfacial energy and increases the mechanical barrier to
coalescence leading to improved thermodynamic stability of
the nanoemulsion formulation (Reiss, 1975). Additionally,
co-surfactants by penetrating into the surfactant ﬁlm and cre-
ating void space among surfactant molecules, increases the
interfacial ﬂuidity (Constantinides and Scalart, 1997).Wider
region is a sign of better self-nanoemulsifying ability. In view
of this fact, the wider nanoemulsiﬁcation region of system D
phase diagram (Fig. 9d) compared to that of the other system
(A, B and C) showed better self nanoemulsiﬁcation property of
the former system. System D yielded nanoemulsion (globuleand (c) mixture in the presence of butylated hydroxyl toluene, (d)
he presence of tocopherol.
Figure 9 Ternary phase diagrams of the selected systems dispersed in water at 25 C. The shaded area represents self-nanoemulsion
region. (a) captex 500: triton X-100: PEG 200 (b) captex 500: triton X-100: PEG 400 (c) captex 500: cremophor RH 40: PEG 200 (d) captex
500: cremophor RH 40: PEG 400.
Table 5 Composition of SNEDDS formulations.
Formulation
no
Captex 500
(% v/v)
Cremophor
RH 40
(% v/v)
PEG 400
(% v/v)
EAPL
complex
(mg/ml)
Tocopherol
(mg/ml)
F1 10 60 30 30 15
F2 20 53 26 30 15
F3 30 46 23 30 15
F4 40 40 20 30 15
F5 50 33 16 30 15
F6 60 26 13 30 15
F7 70 20 10 30 15
F8 80 13 06 30 15
F9 90 06 03 30 15
F10 30 23 46 30 15
F11 40 20 40 30 15
F12 50 16 33 30 15
F13 60 13 26 30 15
F14 30 35 35 30 15
F15 40 30 30 30 15
284 A.M. Avachat, V.G. Patelsize <200 nm) containing as high as 80% oily phase composi-
tion. Nanoemulsions of globule size less than 150 nm were
attained with up to 60% oil phase. However, mean globule size
increased with increasing oil concentration and decreasing
Smix concentration. This phenomenon could be attributed to
the higher concentrations of the Smix required to produce ﬁne
and stable nanoemulsions due to the fact that smaller is the
desired globule size, greater is the surface area and hence,
greater amount of Smix required to stabilize the oil globules.
Owing to wider nanoemulsion region and greater capacity
for the incorporation of oily phase, system D was selected
for further investigation.
3.5. Preparation of EAPL complex SNEDDS
EAPL complex (30 mg) was loaded in selected ﬁfteen
SNEDDS formulations. Composition of the ﬁfteen formula-
tions (F1–F15) is shown in Table 5.
3.6. Optimization of SNEDDS formulation
The best EAPL complex loaded formulation was selected
among ﬁfteen SNEDDS (F1–F15) based on the following
tests.
3.6.1. Robustness to dilution
SNEDDS formulations were subjected to different folds of
dilution in order to mimic the in vivo conditions where the for-
mulation would come across gradual dilution which may affect
drug release proﬁle and the drug may get precipitated at higher
dilutions, which signiﬁcantly retards its permeation or absorp-
tion (Constantinides, 1995). Hence, robustness to dilution was
observed at 50, 100, 250 and 1000 fold dilution with distilledwater. All resulting dispersions showed no cloudiness, separa-
tion or precipitation, for 24 h, conﬁrming their robustness to
different dilution volumes of distilled water. Furthermore, it
also points out to the probability of uniform in vivo drug
release proﬁle when the formulation encounters gradual dilu-
tion (Elnaggar et al., 2009).
3.6.2. Globule size analysis
The droplet size of the emulsion is an important factor in self-
emulsiﬁcation performance as it determines the rate and extent
of drug release, in addition to absorption (Shah et al., 1994;
Gershanik and Benita, 1996). Smaller globule size is highly
Table 6 Mean globule size, polydispersity index and cloud
point of different SNEDDS formulations.
Formulation
no
Mean globule
size (nm)
Polydispersity
index
Cloud point
(C)
F1 269 ± 0.294 0.4892 75–77
F2 139 ± 0.177 0.4128 71–73
F3 284 ± 0.118 0.6538 78–79
F4 106 ± 0.198 0.3388 83–85
F5 374 ± 0.203 0.3892 78–80
F6 419 ± 0.271 0.7382 70–71
F7 489 ± 0.382 0.4829 43–45
F8 476 ± 0.109 0.6938 43–46
F9 577 ± 0.392 0.8723 33–35
F10 124 ± 0.145 0.6717 74–76
F11 187 ± 0.157 0.1084 82–83
F12 539 ± 0.348 0.5993 63–65
F13 579 ± 0.293 0.4912 86–87
F14 121 ± 0.231 0.5882 88–90
F15 167 ± 0.118 0.3018 77–78
The values shown in bold represent most promising batches.
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tion. Results of globule size analysis are shown in Table 6.
Six formulations (F2, F4, F10, F11, F14 and F15) showed
globule size below 200 nm, amongst which F4 shows smallest
globule size (106 ± 0.198) and lower PDI indicating narrow
globule size distribution. The minimum globule size may have
resulted due to minimum ratio of disperse phase to continuous
phase.
3.6.3. Cloud point measurement
The cloud point is a crucial factor in SNEDDS particularly
consisting of non-ionic surfactants as at temperature above
cloud point formulation clarity turns into cloudiness. Even atFigure 10 Zeta potential of ttemperatures higher than the cloud point dehydration of poly-
ethylene oxide moiety of the non-ionic surfactant may occur
resulting in phase separation and there of affecting drug
absorption (Elnaggar et al., 2009). Hence, to circumvent this
occurrence of cloudiness and phase separation, the cloud point
of the formulation should be over 37 C. Many factors such as
amount of each of the oils, surfactants and co-surfactants used,
combination of excipients used, mixing ratio and drug hydro-
phobicity has a great inﬂuence on cloud point (Itoh et al.,
2002; Zhang et al., 2008). All formulations showed cloud point
at a very high temperature (37 C is the base line), indicating
stability at physiological temperature encountered in GIT,
except F9 which exhibited cloudiness at 33–35 C (Table 6).
3.7. Characterization of optimized SNEDDS formulation
3.7.1. Zeta potential measurement
Zeta potential is a very important factor in characterizing
SNEDDS formulation as it can identify the charge of oil glob-
ules in the emulsion (Gershanik and Benita, 2005). High zeta
potential (negative or positive) indicates greater electrostatic
repulsive forces between the globules which prevents the coa-
lescence of nanoemulsion. On the other hand, decrease in such
repulsive forces may lead to phase separation. The zeta poten-
tial of dispersion produced by EAPL complex SNEDDS fol-
lowing the 100 fold dilution with distilled water was found
to be 13.31 mV as shown in Fig. 10, which may be due to
higher concentration of surfactants in optimized EAPL com-
plex SNEDDS, stabilizing the oil droplet resulting in more
repulsive force between droplets. The negative value indicates
that oil globules are negatively charged which may due to
the presence of surfactants and/or co-surfactants. Moreover,
SNEDDS showed conductivity of 0.1042 mS/cm (Fig. 10)
which was higher than 0.50 mS/cm, indicating formation of
o/w emulsion.he SNEDDS formulation.
Figure 11 Drug Release Proﬁles of EAPL complex SNEDDS, EAPL complex and EA suspension in 0.1 N HCl and phosphate buffer
pH 6.8.
286 A.M. Avachat, V.G. Patel3.7.2. Centrifugation test
This test is usually used to determine the stability of the
SNEDDS after nanoemulsion formation (Shaﬁq et al., 2007).
Neither phase separation nor any precipitations were observed
upon centrifugation of EAPL complex SNEDDS, indicating
that a stable nanoemulsion is formed from EAPL complex
SNEDDS.
3.8. Drug release studies
3.8.1. In vitro dissolution proﬁle
In the self-emulsifying systems, the free energy required to
form an emulsion is very low, thereby allowing spontaneous
formation of an interface between the oil droplets and water.
It is suggested that the oil/surfactant/co-surfactant and water
phases effectively swell, decrease the oil droplet size and even-
tually increase the release rate. In-vitro drug release studies
were performed in 0.1 N HCl and pH 6.8 phosphate buffer.
Release patterns (Fig. 11) reveal that EA release was signiﬁ-
cantly higher from EAPL complex SNEDDS (87.09%) as
compared to that from EAPL complex and EA suspension
which did not exceed 42% and 18% respectively after 60 min
in HCl buffer. Similar results were obtained in the case of
phosphate buffer (pH 6.8), where release from EAPL complex
SNEDDS, EAPL complex and EA suspension was about
95%, 44% and 19% respectively. It may be due to the fact that
EAPL complex SNEDDS had resulted in spontaneous forma-
tion of a nanoemulsion with a small mean globule size, result-
ing in a faster rate of drug release into the aqueous phase than
that of EA. Thus, this greater availability of dissolved EA fromFigure 12 In vitro drug release proﬁles of EAPL complex SNEDDS a
6.8 by dialysis bag method.the SNEDDS would lead to higher absorption and oral bio-
availability. These results conﬁrmed the role of SNEDDS for-
mulation in improving EA solubilization and increased in vitro
release.
3.8.2. In-vitro diffusion proﬁle by dialysis bag method
When SNEDDS comes in contact with aqueous medium in
GIT, different forms of solubilized drug are formed including
free molecular state, drug in nanoemulsion and drug in micel-
lar solution. Under such situation to mimic in vivo dissolution
condition, it becomes essential to separate free drug molecules
from those entrapped in the nanoemulsion droplets or
micelles. Therefore, conventional release testing is not com-
pletely adequate to this system so additionally dialysis bag
method was carried out (Zhang et al., 2008). In vitro release
patterns of EA from plain suspension and EAPL complex
SNEDDS in HCl buffer (pH 1.2) and phosphate buffer (pH
6.8) are depicted in Fig. 12. The patterns reveal that release
from EAPL complex SNEDDS was signiﬁcantly higher than
that from EA suspension. After 60 min, drug release from
EAPL complex SNEDDS was about 79% compared to less
than 15% from EA suspension in HCl buffer. Whereas in
phosphate buffer pH 6.8 release from EAPL complex
SNEDDS was about 94% and less than 15% from EA suspen-
sion. Results demonstrated that after formulating SNEDDS,
the release proﬁle of EA was signiﬁcantly improved (6-fold)
although the release was less from both EAPL complex
SNEDDS and EA suspension in dialysis bag method com-
pared to conventional dissolution method, which may be due
to the restriction of the movement across the dialysis bag ofnd EA suspension in HCl buffer pH 1.2 and phosphate buffer pH
Figure 13 In-vitro drug release proﬁle of EAPL complex SNEDDS and EA suspension in FeSSIF and FaSSIF.
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nanoemulsion droplets. This proves the hypothesis that dialy-
sis bag method mimics the in vivo dissolution precisely than
that by conventional dissolution in in vitro evaluation of
SNEDDS.
3.9. Effect of food on release proﬁle of EA
It has been reported in the literature that drug formulated in
SNEDDS circumvents the food effect w.r.t. its release. To
prove this hypothesis dissolution of EA and formulated
SNEDDS was carried out in modiﬁed biorelevant media,
blank FeSSIF and FaSSIF to mimic in vivo conditions.3.9.1. Preparation of modiﬁed biorelevant media, blank FeSSIF
and blank FaSSIF
Blank FeSSIF and FaSSIF media were prepared as discussed
in Section 2.8.1 and were employed to mimic fed and fasted
state condition respectively in in vitro drug release studies to
study the effect of food on release of EA. These media were
modiﬁed as sodium taurocholate and lecithin can interfere in
the analysis and moreover these modiﬁed media produces sim-
ilar results as that by biorelevant media prepared with bile
components thus eliminating the addition of sodium taurocho-
late and lecithin (Zoeller et al., 2007).
3.9.2. In vitro release proﬁle of EA in fed and fasted condition
Release proﬁle of EA from EA suspension and EAPL complex
SNEDDS in fed and fasted state is depicted in Fig 13. Release
of EA from SNEDDS formulation was higher in both FeSSIF
and FaSSIF media (92.18% and 89.75% respectively) with no
signiﬁcant difference between them as compared to that fromFigure 14 Ex-vivo drug permeation proﬁles of EAPL complex SEA suspension, where release was much lesser and signiﬁcantly
different in fed and fasted condition. Results demonstrated
that the food effect from EA suspension was overcome after
the formation of EAPL complex SNEDDS as release from
SNEDDS was same in both fed and fasted condition. This
unaffected release pattern of EA from EAPL complex
SNEDDS may be due to the fact that EAPL complex
SNEDDS maintained EA in preconcentrates and completely
solubilized state, which would have formed nanoemulsions of
sufﬁciently small droplet sizes. Moreover, SNEDDS is sufﬁ-
ciently solubilized by itself; therefore dissolution of SNEDDS
may have not been dependent on pH condition or ionic con-
centration. This suggests that avoidance of the lipid dispersion
process may have overcome the inﬂuence of food on EA
release. Thus, EAPL complex loaded SNEDDS would
improve patient compliance, particularly in patients not able
to take their medicines with food.
3.10. Ex vivo permeability studies
Permeability in gastro intestinal tract of any formulation is a
crucial factor which decides absorption and bioavailability of
drug from that formulation. Hence ex vivo permeability studies
were carried out to determine permeability of EA in stomach
and intestine from SNEDDS and plain drug suspension. The
cumulative % permeation of drug from rat stomach and intes-
tine is shown in Fig. 14. It was observed that the permeation of
the drug was enhanced from the EAPL complex SNEDDS, in
comparison to drug permeation from EA suspension indicat-
ing that permeability of drug was increased after formulating
SNEDDS. About 84% and 94% of drug was permeated from
stomach and intestine respectively in the case of EAPL com-
plex SNEDDS while it was only 23% from stomach andNEDDS and EA suspension from rat stomach and intestine.
288 A.M. Avachat, V.G. Patel30% from intestine in the case of EA suspension. It can be
noted that permeation of the drug from the intestine was
enhanced with SNEDDS, which fulﬁlled our objective of
increasing intestinal permeability for enhancing the bioavail-
ability of EA. Enhanced permeability of EA from SNEDDS
can be attributed to absorption mechanism of oil droplet of
SNEDDS such as passive diffusion, pinocytosis or endocytosis
and their nanometric droplet size providing a large interfacial
surface area for drug release and permeation.
4. Conclusion
The present study has undoubtedly proved the potential effec-
tiveness of SNEDDS for formulating EA with improved
release proﬁle and permeability. The formulated and opti-
mized EAPL complex SNEDDS composed of EAPL complex
(3%), captex (40%), cremophor RH 40 (40%), PEG 400
(20%) and tocopherol (0.15%) was robust to dilution in dis-
tilled water at different folds of dilution indicating robustness
to dilution and also showed mean globular size, cloud point
and zeta potential within the acceptable range. Drug was
found to be stable in lipid system in the presence of tocopherol
while, EAPL complex prepared by anti-solvent served dual
advantages of increasing drug loading as well as solubility.
In vitro dissolution and ex vivo permeability studies revealed
improved release proﬁle and permeation of EA, respectively
from EAPL complex SNEDDS compared to EA suspension.
Moreover, EAPL complex SNEDDS overcame food effect
on release pattern of EA. The current investigation may serve
as a promising approach for the formulation development of
other drugs or phytoconstituents which have limited solubility
in both, water as well as lipids.
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